Convergence of innate immunity and insulin resistance as evidenced by increased nucleotide oligomerization domain (NOD) expression and signaling in monocytes from patients with type 2 diabetes

Cytokine

Volumn 64, Issue 2, 2013, Pages 564-570

  Shiny, Abhijit ^a   Regin, Bhaskaran ^a   Balachandar, Venketesan ^a   Gokulakrishnan, Kuppan ^a   Mohan, Viswanathan ^a   Babu, Subash ^b   Balasubramanyam, Muthuswamy ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

^b National Institutes of Health International Center for Excellence in Research   (India)

Author keywords

Inflammation; Innate immunity; Insulin resistance; Nucleotide oligomerization domain (NOD); Type 2 diabetes

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD11B ANTIGEN; CD36 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; NUCLEOTIDE; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ISOLATION; CELL STIMULATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; INSULIN RESISTANCE; MONOCYTE; NOD1 GENE; NOD2 GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

GLYCATED HEMOGLOBIN; HBA1C; HOMA; HOMEOSTASIS ASSESSMENT MODEL; IEDAP; IGT; IL-6; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; INTERLEUKIN-6; MDP; MURAMYL DIPEPTIDE; NFΚΒ; NGT; NOD; NORMAL GLUCOSE TOLERANCE; NUCLEAR FACTOR KAPPA BETA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN; NUCLEOTIDE OLIGOMERIZATION DOMAIN (NOD); ODDS RATIO; OR; PATTERN RECOGNITION RECEPTOR; PEPTIDOGLYCAN; PGN; PRR; RECEPTOR INTERACTING PROTEIN KINASE 2; RIPK2; T2DM; TLR; TNF-Α; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR - ALPHA; TYPE 2 DIABETES; TYPE 2 DIABETES MELLITUS; Γ-D-GLUTAMYL-MESO DIAMINOPIMELIC ACID;

ADULT; ANTIGENS, CD11B; ANTIGENS, CD36; CYTOKINES; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MIDDLE AGED; MONOCYTES; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; TRANSCRIPTION FACTORS;

EID: 84885178953     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.08.003     Document Type: Article

References (38)

1. Shi H., Kokoeva M., Inouye K., Tzameli I., Yin H., Flier J. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
2. Nakamura T., Furuhashi M., Cao P.L.H., Tuncman G., Sonenberg N., Gorgun C., et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010, 140:338-348.
3. Tsukumo D.M.L., Carvalho-Filho M.A., Carvalheira J.B.C., Prada P.O., Hirabara S.M., Schenka A.A., et al. Loss-of-function mutation in toll like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
4. Radin M.S., Sinha S., Bhatt B.A., Dedousis N., ODoherty R.M. Inhibition or deletion of the lipopolysaccharide receptor toll like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia 2007, 51:336-346.
5. Girardin S., Boneca I., Carneiro L., Antignac A., Jehanno M., Viala J., et al. NOD1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003, 300:1584-1587.
6. Anstett M.M., Muller P., Albrecht T., Nega M., Wagener J., Gao Q., et al. Staphylococcal peptidoglycan co-localizes with Nod2 and TLR2 and activates innate immune response via both receptors in primary murine keratinocytes. PloS One 2010, 5:e13153.
7. Carneiro L.A.M., Travassos L., Philpott D.J. Innate immune recognition of microbes through Nod1 and Nod2: implications for disease. Microbes Infect 2004, 6:609-616.
8. Carneiro L.A.M., Magalhaes J.G., Tattoli I., Philpott D.J., Travassos L.H. Nod-like proteins in inflammation and disease. J Pathol 2008, 214:136-148.
9. Chamaillard M., Girardin S., Viala J., Philpott D. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell Microbiol 2003, 5:581-592.
10. Inohara N., Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003, 3:371-382.
11. Inohara N., Koseki T., Lin J., del Peso L., Lucas P., Chen F., et al. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 2000, 275:27823-27831.
12. Abbott D.W., Andrew W., Asara M.J., Cantley C.L. The crohns disease protein, Nod2, Requires Rip2 in order to induce ubiquitinylation of a novel site on nemo. Curr Biol 2004, 14:2217-2227.
13. Yibin Y., Yin C., Pandey A., Abbott D., Sassetti C., Kelliher M. Nod2 pathway activation by MDP or mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem 2007, 282:36223-36229.
14. Park J.H., Kim Y.G., McDonald C., Kanneganti T., Hasegawa M., Malapel M.B., et al. Rick/Rip2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 2007, 178:2380-2386.
15. Schertzer J., Tamrakar A., Magalhaes J., Pereira S., Bilan P., Fullerton M., et al. Nod1 activators link innate immunity to insulin resistance. Diabetes 2011, 60:2206-2215.
16. Zhou R., Yazdi A., Menu P., Tschopp J. A role for mitochondria in Nlrp3 inflammasome activation. Nature 2011, 469:221-225.
17. Vandanmagsar B., Youm Y., Ravussin A., Galgani J., Stadler K., Mynatt R., et al. The Nlrp3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011, 17:179-188.
18. Deepa M., Pradeepa R., Rema M., Mohan A., Deepa R., Shanthirani S., et al. The Chennai urban rural epidemiology study (CURES)-study design and methodology (urban component) (CURES-1). J Assoc Phys Ind 2003, 51:863-870.
19. Alberti K., Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
20. Stroh T., Batra A., Glauben R., Fedke I., Erben U., Kroesen A., et al. Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes. J Immunol 2008, 181:3620-3627.
21. Zhao L., Hu P., Zhou Y., Purohit J., Hwang D. Nod1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes. Am J Physiol 2011, 301:587-598.
22. Nardo D.D., Latz E. Nlrp3 inflammasomes link inflammation and metabolic disease. Trends Immunol 2011, 32:373-379.
23. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M., et al. Fatty acid-induced Nlrp3-Asc inflammasome activation interferes with insulin signaling. Nat Immunol 2011, 12:408-415.
24. Tamrakar A., Schertzer J., Chiu T., Foley K., Bilan P., Philpott D., et al. Nod2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology 2010, 151:5624-5637.
25. Miller L., Bainton D., Borregaard N., Springer T. Stimulated mobilization of monocyte Mac-1 and P150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface. J Clin Invest 1987, 80:535-544.
26. Cifarelli V., Libman I., Deluca A., Becker D., Trucco M., Luppi P. Increased expression of monocyte Cd11b (Mac-1) in overweight recent-onset type 1 diabetic children. Rev Diabet Stud 2007, 4:112-117.
27. Van Oostrom A.J., Van Wijk J., Sijmonsma T., Rabelink T., Castro Cabezas M. Increased expression of activation markers on monocytes and neutrophils in type 2 diabetes. Neth J Med 2004, 62:320-325.
28. Cipolletta C., Ryan K., Hanna E., Trimble E. Activation of peripheral blood CD14+ monocytes occurs in diabetes. Diabetes 2005, 54:2779-2786.
29. Sun Y., Scavini M., Orlando R., Murata G., Servilla K., Tzamaloukas A., et al. Increased CD36 expression signals monocyte activation among patients with type 2 diabetes. Diabet Care 2010, 33:2065-2067.
30. Kobayashi K., Inohara N., Hernandez L., Galan J., Nunez G., Janeway C., et al. Rick/Rip2/Cardiak mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002, 416:194-199.
31. Lee H.M., Kim J.J., Kim H., Shong M., Ku B., Jo E.K. Upregulated Nlrp3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013, 62:194-204.
32. Zhao L., Kwon M.J., Huang S., Lee J., Fukase K., Inohara N., et al. Differential modulation of NODs signaling pathways by fatty acids in human colonic epithelial Hct116 cells. J Biol Chem 2007, 282:11618-11628.
33. Cheng G., Sun J., Fridlender Z.G., Wang L.C., Ching L.M., Albelda S. Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived Xanthone drug 56-dimethylxanthenone-4-acetic acid (Vadimezan). J Biol Chem 2010, 285:10553-10562.
34. Dasu M., Devaraj S., Zhao L., Hwang D., Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008, 57:3090-3098.
35. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010, 11:136-140.
36. Gokulakrishnan K., Mohanavalli K., Monickaraj F., Mohan V., Balasubramanyam M. Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and type 2 diabetes patients. Mol Cell Biochem 2009, 324:173-181.
37. Biswas A., Ocwieja T.P., Kobayashi K. Nod2: a key regulator linking microbiota to intestinal mucosal immunity. J Mol Med 2012, 90:15-24.
38. Cani P., Osto M., Geurts L., Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012, 3:279-288.